The Oxyven-Device Dr. H.S. Regelsberger GmbH & Co. KG was founded in the year 1975. Dr. med. Regelsberger (neurologist/neurosurgeon from Detmold) has done intensive research on intravenous application of minute amounts of oxygen and has been able to determine its therapeutic effect. Thus, it became his great desire to standardize the implementation of this particular application with its sophisticated device.
Application methods have been developed in continuous stages to make the safety related highly sophisticated oxygen-application device from company Helkueb OHG available.
It is dose dependable and best suitable for flow–monitoring intravenous oxygen-insufflation in the medicine sector. Optimum support for our customers in the supervision of the practical application of this specific application device in practice is of particular importance to us. In this specific way, the customers receive a detailed instruction in their practice.
This specified therapy founded by Dr. med. Regelsberger has been implemented by over 1000 therapists - according to details of the international society for oxygen-nierungstherapie e.V. (www.oxyvenierung.com).
You can get indications and details to the thirty year research development in the therapy method of the intravenous oxygen-application carried out by Dr. med. H.S. Regelsberger in
would you please inform yourself in the appropriate regulations, panels or by the International Society of Oxyvenierungstherapie e.V.
Applimed-O2 1000 controls the exact and reliable application of medical oxygen in the intravenous method in a dosage in a range between 1 to 2ml/min. Oxygen is a very important component in complementary medicine.
Oxygen leads to the intensified formation of the blood flow and antithrombotic hormone Prostacyclin. It is formed in the lung endothelium. Result is a strong vascular dilation in the complete body structure (an average increase of Prostacycline of more than 800%; according to an article written by Prof. Dr. J.C. Frölich - Hannover Medical School).
An eosinophilia is initiated by applying oxygen. The eosinophilic granulocytes are capable of forming the 15-lipoxygenase-1, with oxygen release from the arachidonic acid cascade. The leukotriene synthesis is being blocked by this process. The anti-inflammatory effect has been confirmed by the work of Prof. Dr. sc. Med. Hartmut Kühn - Charite Berlin. Further literature is available through our: Contact.
1. Internationaler O2 – Kongress
61231 Bad Nauheim
Zertifizierungskurs für Oxyvenierung
Kaarster Straße 250
Leitung: Dr. med. Dirk Wiechert , HP Stefan Marzinowski
Should you need further information to our oxygen-application and to our oxyven therapy according to Dr. med. Regelsberger. – Just leave us a message; we will enjoy supporting you.
Dr. med. H.S. Regelsberger GmbH & Co. KG
Brookstr. 31 A
Telephone: +49 (0) 591 / 901 108-0
Fax: +49 (0) 591 / 901 108-20